Plaque Psoriasis
Bimzelx 320 mg, 2 mL single-injection option now available for multiple indications
The single-injection 2 mL prefilled syringe and autoinjector for Bimzelx 320 mg is now available, UCB announced in a press release.
Celltrion's Steqeyma nabs FDA approval as seventh Stelara biosimilar
The FDA has approved the Stelara biosimilar Steqeyma for the treatment of adults and children with plaque psoriasis and psoriatic arthritis and adults with Crohn’s disease and ulcerative colitis, Celltrion announced in a press release.
Johnson & Johnson submits sBLAs for Tremfya for two pediatric indications
Johnson & Johnson has submitted two supplemental biologics license applications to the FDA for Tremfya for the treatment of plaque psoriasis and juvenile psoriatic arthritis in children, the company announced in a press release.
FDA approves Yesintek, sixth Stelara biosimilar; launch slated for February
The FDA has approved the Stelara biosimilar Yesintek for indications matching the reference product, with a commercial launch date expected for early 2025, according to a press release from Biocon Biologics.
Oral IL-23 inhibitor improves psoriasis through 1 year
Patients with moderate to severe psoriasis experienced higher rates of skin clearance through 1 year with oral JNJ-77242113 treatment compared with placebo, according to phase 2 study results.
Oral IL-23 inhibitor icotrokinra shows efficacy for plaque psoriasis
New, positive topline data found icotrokinra to be effective for the treatment of moderate to severe plaque psoriasis in patients aged 12 years and older, Protagonist Therapeutics and Johnson & Johnson announced.
FDA expands approval of Stelara biosimilar Selarsdi to include UC, Crohn’s disease
The FDA approved the Stelara biosimilar, Selarsdi, as a 130 mg/26 mL single-dose IV infusion for adult patients with Crohn’s disease and ulcerative colitis, Alvotech and Teva Pharmaceuticals announced in a press release.
FDA approves higher-dose Bimzelx prefilled syringes, autoinjectors
The FDA has approved 320 mg pre-filled syringes and autoinjectors of Bimzelx for the treatment of active psoriatic arthritis with coexisting moderate-to-severe plaque psoriasis, according to a press release from UCB.
Novel TYK2 inhibitor ICP-488 shows efficacy, safety in plaque psoriasis
ICP-488 demonstrated “excellent” efficacy and safety for the treatment of moderate to severe plaque psoriasis in adults, InnoCare Pharma announced in a press release.
TYK-2 inhibitor effective over 7 months for treatment of plaque psoriasis
ESK-001 demonstrates continued efficacy for the treatment of moderate to severe plaque psoriasis over the span of 7 months, according to a late-breaker presentation at the European Academy of Dermatology and Venereology Congress.